<h3>在 TipRanks 上享受 55% 折扣</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级为市场领袖的投资组合，使用智能投资者精选</li>
</ul>
<p>杭州泰格医药咨询有限公司 H 股（(HK:3347)）刚刚发布了一项更新。</p>
<p>杭州泰格医药咨询公司在市场对其控股股东、董事长叶小平和董事曹晓春是否遵守过去股权变动披露规则的猜测后，发布了澄清。公司强调，这些事项涉及两位个人的历史股权变动披露，已通过之前的减持公告、定期报告和简要股权变动报告公开宣布。</p>
<p>公司强调，针对这些历史披露的持续监管调查与其基础业务运营无关，不会影响其正常活动。它还敦促股东和潜在投资者仅依赖公司官方公告获取集团信息，并在当前审查中谨慎交易其股票。</p>
<p>关于（HK:3347）股票的最新分析师评级为买入，目标价为 HK$55.00。要查看杭州泰格医药咨询有限公司 H 股的完整分析师预测列表，请参见 HK:3347 股票预测页面。</p>
<p><strong>关于杭州泰格医药咨询有限公司 H 股的更多信息</strong></p>
<p>杭州泰格医药咨询有限公司是一家在中国注册的公司，上市于香港，并通过集团结构运营。它为制药和生命科学行业提供专业服务，定位为临床开发合同研究及相关咨询的关键参与者。公司通过受监管的资本市场披露为国内外客户提供服务。</p>
<p><strong>平均交易量：</strong> 1,634,388</p>
<p><strong>技术情绪信号：</strong> 卖出</p>
<p><strong>当前市值：</strong> HK$44.48B</p>
<p>要对 3347 股票进行全面评估，请访问 TipRanks 的股票分析页面。</p>

泰格医药

<p>杭州泰格医药咨询有限公司澄清，针对其主要股东历史股权披露的监管调查不会影响其业务运营。公司向股东和潜在投资者保证，应依赖官方公告获取信息，并在交易中保持谨慎。泰格医药（HK:3347）的最新分析师评级为买入，目标价为 55.00 港元。该公司专注于为制药和生命科学领域提供服务</p>

<h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级为市场领袖的投资组合，使用智能投资者精选</li>
</ul>
</div><p>Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ) just unveiled an update.</p>
<div class="lb-trans"><p>杭州泰格医药咨询有限公司 H 股（(HK:3347)）刚刚发布了一项更新。</p>
</div><p>Hangzhou Tigermed Consulting has issued a clarification following market speculation about whether its controlling shareholders, chairman Ye Xiaoping and director Cao Xiaochun, complied with disclosure rules on past shareholding changes. The company stresses that these matters concern historical equity change disclosures by the two individuals, which it says were publicly announced through prior reduction notices, periodic reports and a brief equity change report.</p>
<div class="lb-trans"><p>杭州泰格医药咨询公司在市场对其控股股东、董事长叶小平和董事曹晓春是否遵守过去股权变动披露规则的猜测后，发布了澄清。公司强调，这些事项涉及两位个人的历史股权变动披露，已通过之前的减持公告、定期报告和简要股权变动报告公开宣布。</p>
</div><p>The company emphasizes that the ongoing regulatory investigation into these historical disclosures does not relate to its underlying business operations and will not affect its normal activities. It also urges shareholders and potential investors to rely solely on official company announcements for information on the group and to exercise caution when trading its shares amid the current scrutiny.</p>
<div class="lb-trans"><p>公司强调，针对这些历史披露的持续监管调查与其基础业务运营无关，不会影响其正常活动。它还敦促股东和潜在投资者仅依赖公司官方公告获取集团信息，并在当前审查中谨慎交易其股票。</p>
</div><p>The most recent analyst rating on (HK:3347) stock is a Buy with a HK$55.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.</p>
<div class="lb-trans"><p>关于（HK:3347）股票的最新分析师评级为买入，目标价为 HK$55.00。要查看杭州泰格医药咨询有限公司 H 股的完整分析师预测列表，请参见 HK:3347 股票预测页面。</p>
</div><p><strong>More about Hangzhou Tigermed Consulting Co., Ltd. Class H</strong></p>
<div class="lb-trans"><p><strong>关于杭州泰格医药咨询有限公司 H 股的更多信息</strong></p>
</div><p>Hangzhou Tigermed Consulting Co., Ltd. is a China-incorporated company listed in Hong Kong and operates through a group structure. It provides professional services to the pharmaceutical and life sciences sectors, positioning itself as a key player in contract research and related consulting for clinical development. The company serves both domestic and international clients through regulated capital market disclosures.</p>
<div class="lb-trans"><p>杭州泰格医药咨询有限公司是一家在中国注册的公司，上市于香港，并通过集团结构运营。它为制药和生命科学行业提供专业服务，定位为临床开发合同研究及相关咨询的关键参与者。公司通过受监管的资本市场披露为国内外客户提供服务。</p>
</div><p><strong>Average Trading Volume:</strong> 1,634,388</p>
<div class="lb-trans"><p><strong>平均交易量：</strong> 1,634,388</p>
</div><p><strong>Technical Sentiment Signal:</strong> Sell</p>
<div class="lb-trans"><p><strong>技术情绪信号：</strong> 卖出</p>
</div><p><strong>Current Market Cap:</strong> HK$44.48B</p>
<div class="lb-trans"><p><strong>当前市值：</strong> HK$44.48B</p>
</div><p>For a thorough assessment of 3347 stock, go to TipRanks’ Stock Analysis page.</p>
<div class="lb-trans"><p>要对 3347 股票进行全面评估，请访问 TipRanks 的股票分析页面。</p>
</div>

泰格医药称对主要股东的调查不会影响公司的运营